Resources

Scientists at the Joslin Diabetes Center in Boston have found that a defect in the beta cells that make and release insulin has implications for the failure of these cells and the development of type 2 diabetes.

Lack of exposure to the sun could play a role in development of type 1 diabetes and that vitamin D supplementation in early childhood may offer protection against the development of type 1 diabetes.

Food with high antioxidant concentrations seems to have a protective effect, improving oxidative stress-mediated detrimental effects on the vicious circle among obesity, and insulin.

The diabetes medication rosiglitazone has been associated with a reduction in the likelihood of developing the eye disease called proliferative diabetic retinopathy. A study published in the June issue of Archives of Ophthalmology also found that diabetes patients using the drug were less likely to have reductions in visual acuity …

Loading up on protein and carbohydrates at breakfast may help obese patients with metabolic syndrome stick to a low-calorie, low-carbohydrate diet the rest of the day, researchers found.

Patients with hypertension who monitored their blood pressure from home and received Web-based pharmacist care showed greater improvement in blood pressure control than patients who received usual care, according to a study.

We ran into Dr. Sheri Colberg, Ph.D., FACSM at ADA in San Francisco and we were discussing the success patients feel when they do something physical and how many medical professionals have used her printouts to help their patients. This week she brings us Lower-body resistance training exercises: One-leg press …

Alogliptin, an investigational once-daily oral drug for type 2 diabetes, showed good efficacy and safety both as monotherapy and together with standard agents, researchers in five phase III trials stated at ADA Scientific Sessions.

Pioglitazone (Actos) may prevent or delay progression to diabetes for patients with pre-diabetes by 81%, researchers found.

Nearly half of patients taking exenatide (Byetta) for type 2 diabetes for more than a year in a small study discontinued it because of loss of efficacy, although many were combining it with insulin off-label. See Publisher’s Comments